Phathom Pharmaceuticals

We’re excited to have received a 3rd #FDAapproval of our first-in-class medicine! This approval is a welcomed development for #GERD patients, bringing a new treatment for heartburn relief in Non-Erosive GERD. Read more about what this means for the millions of people with this disease: https://bit.ly/4cLc2qe

This summer, we had the pleasure of welcoming Akachukwu Chukwuma and Dennis Means as Medical Affairs summer interns! Both PharmD candidates at Howard University, Akachukwu and Dennis spent their summers working on various medical and clinical affairs-related projects and learning more about the pharmaceutical industry. Click below to learn about Akachukwu and Dennis’ summers at Phathom, their favorite aspects of the #PhathomPhamily, and their advice for future students looking to enter the field. #LifeatPhathom #Internship #PHATatWork #SummerInternship 

We are proud to share that our novel treatment for #GERD has been nominated by Healio Gastroenterology for a 2024 Disruptive Innovators Award in the Industry Breakthrough category.   Thank you for this recognition, Healio – it is an honor to be included alongside our peers who are working to push the status quo toward the betterment of the field.   Cast your vote now through August 31: https://bit.ly/4dyLeKj #HealioInnovators 

In celebration of #InternationalDogDay on August 26, swipe to meet some of our adorable, furry Phathom Phamily members! 🐾❤️ We hope our four-legged pHriends enjoy a day of endless treats and belly rubs. We think dogs (and pets in general) are important members of the Phamily, so we’ve made sure our inclusive benefits apply to our furry companions as well! Learn more about pet insurance and other great #phamily benefits that #LifeAtPhathom has to offer: https://lnkd.in/gjbj_5wQ #PHATPets #DogDaysofSummer #DogDay

We are incredibly proud to announce that Phathom has been certified as a Great Place to Work! This distinguished recognition comes from the voices of our #PhathomPhamily, with ~9 out of 10 employees surveyed expressing that Phathom is a great place to work. This reflects our commitment to creating a positive, inclusive, and dynamic workplace. Thank you to our dedicated team for continuing to make Phathom such a phantastic place! #GreatPlaceToWork #GPTWCertified #PHATandHappy Great Place To Work US

Last month, the GI community mourned the loss of Nobel laureate J. Robin Warren, whose groundbreaking work reshaped our understanding of peptic ulcers. His discovery that Helicobacter pylori (H. pylori) is the root cause of most peptic ulcers was a turning point in medical history, paving the way for innovative treatments that have helped to improve eradication rates for this serious infection and help alleviate the suffering of millions of people worldwide. As a company dedicated to advancing novel therapies for acid-related disorders, including the treatment of H. pylori, we are deeply grateful for Dr. Warren’s relentless pursuit of science and his enduring impact on the medical community. His lasting legacy will continue to inspire and guide us in our mission to change the landscape in GI.  Rest in peace, Dr. Warren, and thank you for your extraordinary contributions. 

We’re proud to share that we’ve been nominated by the 2024 Prix Galien USA Awards for Best Pharmaceutical Product! It’s an honor to be included among these esteemed organizations that are leading the way in the healthcare industry and improving the lives of millions globally. The Prix Galien USA Award is America’s preeminent prize acknowledging the leading-edge of scientific advances in life sciences. Thank you to The Galien Foundation for this recognition and congratulations to our fellow nominees. Read more: https://bit.ly/3AiBVzt #PrixGalien #Innovation

Today we reported financial results for the second quarter of 2024 and provided business updates. Learn more about the work we are doing, including bringing to market the first and only FDA-approved treatment of its kind for #GERD. Read the press release: https://bit.ly/3ylJCUV

Our novel treatment is now #FDAapproved to relieve heartburn for adults with Non-Erosive GERD, the largest subset of #GERD. We’re excited to offer a new treatment option for the ~45 million adults in the U.S. living with this disease. Learn more about what this therapy means for the future of GERD treatment: https://bit.ly/4cLc2qe

We are pleased to share that CVS Caremark, the largest U.S. pharmacy benefit manager (PBM), has added our novel GERD therapy to their national commercial formularies. Today, over 116 million commercially covered lives have access to our novel treatment. Learn more about this #NEWS here:  https://bit.ly/3LJrwPC